What Processing Parameters Govern Sterile Parenteral Formulation of Maxingshigan Extract?

Maxingshigan Injection Veterinary Grade API is supplied as an injection-grade aqueous concentrate of Ephedrae Herba, Gypsum Fibrosum, Armeniacae Semen Amarum, and Glycyrrhizae Radix et Rhizoma, standardized to ephedrine alkaloid and amygdalin marker content. The concentrate is not a direct injectable; downstream sterile formulation requires dilution to 20–30% v/v in Water for Injections at 45–55°C. The pH is adjusted with 0.1 M sodium hydroxide or citric acid to a narrow window of pH 5.0–5.5. This window is a process determinant rather than a formulation preference: below pH 4.5, glycyrrhizic acid precipitates as a viscous sediment, while above pH 6.5, the cyanogenic glycoside fraction and amygdalin hydrolysis accelerate, increasing benzaldehyde and hydrogen cyanide degradation markers. Calcium sulfate from Gypsum Fibrosum saturates the solution, so processing water must not introduce bicarbonate alkalinity above 50 mg/L CaCO₃ to avoid calcium carbonate nucleation. Compliance for the sterile route is anchored to the relevant pharmacopoeial general chapters, including Ph. Eur. 2.6.1 for sterility and Ph. Eur. 2.6.14 for bacterial endotoxins; fill operations follow EU GMP Annex 1 with Grade B background and Grade A LAF. The diluted solution is treated with 0.1% w/v activated carbon at 60°C for 30 minutes, passed through a depth filter, and then through 0.45 µm/0.22 µm polyethersulfone capsule filters. Terminal steam sterilization at 121°C for 15 minutes is used only when the batch-scale validation confirms ephedrine HCl recovery ≥ 95%; otherwise aseptic filtration is specified. Production-scale fill lines record that hold times beyond 8 hours before filtration can produce visible calcium sulfate crystal growth, so preparation lots are generally split at 500 L. Terminal presentations are 10 mL, 20 mL, and 100 mL neutral borosilicate vials or ampoules for porcine and bovine respiratory indications. The injection is incompatible with sulfonamide sodium parenteral fluids because co-administration produces precipitate; ephedrine content also requires import documentation under controlled precursor rules in multiple jurisdictions.

In broiler and layer integrations that administer respiratory support through closed nipple-drinker systems, the limiting unit operation is not the marker content of the API but the rate and completeness of solubilization in hard water at ambient temperature. Maxingshigan dry extract API for water-soluble powder is spray-dried onto maltodextrin or soluble starch, with loss on drying ≤ 4%. The formulation input range is 4–8% w/w of the finished powder, with anhydrous dextrose q.s. to 100%, PVP K30 at 1–2%, and fumed silica at 0.5–1% as flow control. If the dry extract particle fraction above 150 µm exceeds 10%, pre-milling on a pin mill fitted with a 0.5 mm screen is required before blending. Compliance is typically demonstrated against the Chinese Veterinary Pharmacopoeia soluble powder monograph for content uniformity and against VICH GL18 for residual solvent testing. The blend is mixed in a horizontal ribbon mixer at 60–70% fill volume for 10–12 minutes, discharged at ≤ 40% RH, and packed into 100 g, 500 g, or 1 kg foil-lined pouches. For farms with water hardness above 300 mg/L CaCO₃, the formula includes citric acid at 1–2% to reduce drinker-water pH to 5.5–6.0; without acidification, calcium sulfate fines from the herbal extract can deposit in pressure regulators and nipple drinkers. Sodium bicarbonate-buffered house water is a documented incompatibility because it precipitates calcium carbonate from the gypsum fraction and blocks drinker lines. Terminal products are 100 g, 500 g, and 1 kg water-soluble powder sachets; the same API grade can be converted into 1 L and 5 L oral solutions using a sorbitol-glycerin vehicle, but pH must remain below 6.0 at use dilution to limit amygdalin hydrolysis.

With a Direct Compression Route Skipped, What Happens Inside a 2-Ton Ribbon Mixer During Dry Premix Dilution?

Feed premix intermediates containing Maxingshigan dry extract at 5–10 kg/t final feed are produced by progressive geometric dilution through a two-stage system. Stage one compacts the API with rice hulls, microcrystalline cellulose, and calcium silicate at 1:10 before introduction to a 2-ton horizontal ribbon mixer operating at 18 rpm and 60–70% fill volume. The critical acceptance criterion is coefficient of variation ≤ 5% for marker ephedrine across 10 sampling points. Single-stage mixing is not sufficient because the dry extract has bulk density 0.45–0.55 g/cm³, whereas soybean meal carriers are 0.62–0.68 g/cm³; density mismatch causes stratification after discharge. Compliance for EU medicated feed is under Regulation (EU) 2019/4, including homogeneous incorporation and carryover controls, rather than feed additive rules; the material is not a zootechnical feed additive. Moisture at mixer discharge is kept ≤ 12% for mash and ≤ 10% before pelleting, with moisture determined per ISO 6496. Pelleting is run at a conditioning temperature of ≤ 65°C and retention time of 45 seconds; temperatures above 70°C produce measurable amygdalin loss and darkening of the pellet surface. In high-humidity zones above 60% RH, uncoated API forms a hard layer on mixer shafts within 6 hours; this is an observed production bottleneck requiring line stoppage and steam-cleaning of the shaft. Terminal products are 5% and 10% premixes in 25 kg paper sacks with PE liner for nursery and grower pigs. In jurisdictions where ephedra-containing botanical preparations are not registered veterinary medicines, medicated feed use is not permitted; formulators must verify national controls before shipment.

For pre-ruminant calves with enzootic pneumonia, the dry extract is formulated into granules because this route avoids the inhalable dust fraction generated by water-soluble powders while permitting direct oral drenching or top dressing onto starter feed. Maxingshigan granule API input is 15–25% w/w of the finished granule mass. The powder blend consists of lactose monohydrate 35–45%, microcrystalline cellulose 20–25%, sodium starch glycolate 2–4%, and povidone K30 as binder at 1–2%. Wet granulation is performed in a high-shear granulator with impeller speed 300–400 rpm and chopper 1500–2000 rpm; purified water is added at 18–20% w/w, with endpoint determined by torque rise 8–12% above the dry blend baseline. Drying in a fluid-bed dryer at 50°C inlet air to loss on drying ≤ 3% protects the amygdalin fraction from thermal degradation. The dried granules are sized through 12/20 mesh and packed as 10 g triple-foil stick packs, 100 g HDPE jars, or 1 kg pouches. Compliance is assessed by the Chinese Veterinary Pharmacopoeia granule monograph for moisture, content uniformity, and microbial limits, with USP 711 dissolution used for marker release where the importing jurisdiction follows USP general chapters. This section is shorter than the injectable route because the technical path is well-established and the only critical transfer point is moisture ingress during stick-pack filling below 35% RH. Prolonged oral administration of glycyrrhizin is recognized to cause sodium retention in calves, so treatment duration is ordinarily limited to 7 days and serum sodium is monitored when administration exceeds 5 days.

Tablet and Capsule Compression Without Exceeding the Hygroscopicity Limit of Spray-Dried Botanical Extract

Direct compression of Maxingshigan dry extract above 20% w/w is not recommended because the extract acts as a self-binder and picks up moisture within 15 minutes at 50% RH, causing capping on rotary presses. Tablet and capsule formulations therefore use slugging or dry granulation: API input is 10–20% w/w, dibasic calcium phosphate dihydrate 40–55%, microcrystalline cellulose 20–30%, croscarmellose sodium 2–5%, colloidal silicon dioxide 0.5–1.0%, and magnesium stearate 0.5–1.0%. Compression is run at 12–18 kN on a 12-station rotary press to target hardness 60–80 N, thickness 3.5–4.5 mm, and friability ≤ 0.8% per USP 1216. Disintegration is controlled by USP 701 and is specified as ≤ 30 minutes in water at 37°C. For capsules, the granulate is filled into size 3 or size 1 hard gelatin or HPMC capsules at 60–70% of maximum fill volume; low-fill capsules generate dust and electrostatic adherence on high-speed dosator machines. Compliance for non-food-producing equine and companion animal applications follows current veterinary GMP and the relevant national pharmacopoeial general chapters, with certificates of analysis stating microbial limits, heavy metals, and residual solvent profile according to VICH GL18. Terminal products are 300 mg, 500 mg, and 750 mg tablets in aluminum/PVC cold-form blisters, and 200 mg and 400 mg hard capsules in HDPE bottles with 1 g silica gel desiccant. Magnesium stearate above 1.0% is a documented compression failure mode because it combines with the extract’s free calcium to form hydrophobic agglomerates that slow disintegration beyond specification.

Oral Solution pH Windows and the Preservative Partitioning Behaviour of Maxingshigan Liquid API

Maxingshigan liquid API in oral solutions is maintained at 20–30% v/v in a co-solvent system of sorbitol 40–55%, glycerin 5–10%, and purified water q.s. to 100%. The solution pH is adjusted to 4.8–5.5 with citric acid; this range keeps glycyrrhizic acid soluble while suppressing benzaldehyde and hydrogen cyanide development from the cyanogenic glycoside fraction. Preservative selection is constrained because polysorbate 80 above 0.1% inactivates methylparaben; the standard system uses methylparaben 0.08% and propylparaben 0.02%, with preservative challenge testing per Ph. Eur. 5.1.3. The liquid is compounded in a jacketed stainless mixing vessel at 55–60°C, cooled to 25°C before final pH adjustment, and passed through a 10 µm cartridge filter to remove particulate calcium sulfate without removing active markers. Filling is into 1 L, 5 L, and 25 L amber polyethylene terephthalate or HDPE jerrycans with induction-sealed closures; the light-protective container is required because ephedrine alkaloids in aqueous solution are susceptible to photodegradation under ICH Q1B conditions. The terminal products are oral dosing solutions for calves, lambs, foals, and pigs when individual animal administration is preferred over drinking-water mass medication. Sodium bicarbonate buffer should not be substituted for citric acid; bicarbonates reduce the solution’s pH-buffering capacity at use dilution and permit visible precipitation at >500 mg/L CaCO₃ equivalent. Published data for this specific liquid configuration is limited outside Chinese-language technical bulletins; batch-specific validation is required for the pH and preservative levels stated here.